Compare ADMA Biologics Inc (ADMA) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Johnson Controls International PLC — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Johnson Controls International PLC trades at $154.72 (market cap $93.74B). The key difference: Johnson Controls International PLC is far larger — about 42.2× ADMA Biologics Inc's market cap, and Johnson Controls International PLC pays a 1.03% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | JCI | |
|---|---|---|
Market Cap | $2.22B | $93.74B |
Sector | Health | Industrials |
52-Week High | $20.38 | $154.76 |
52-Week Low | $7.60 | $103.52 |
Enterprise Value | $2.29B | $102.58B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
JCI trades at $150.70, down 0.99% on the day, with a strong bullish technical signal from moving averages. The company reported robust Q3 2026 earnings, beating estimates with $1.42 EPS and raising full-year guidance, driven by double-digit organic sales growth and record backlog. Analyst consensus is strongly positive with a $168.25 price target and no sell ratings. Recent news highlights efficiency leadership and AI-related thermal management innovations.
The outlook remains favorable given earnings momentum and strategic positioning in high-demand sectors like data centers. Key risks include execution on growth targets and macroeconomic sensitivity. The stock presents a growth opportunity supported by fundamental strength and bullish sentiment, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
